On Tuesday, a few unusual option trades were made. Stock traders bought 2,791 puts on the stock. This is a 34% increase compared to an average daily volume 2,087 put option.
Insider Activities at Catalent
In a deal dated January 23, I sold 643 Catalent shares. Stock was sold for $31,738.48 at a price of $49.36 on average. After the sale was completed, the insider owns directly 16,452 shares of the company valued at $812 070.72. Hedge funds have made recent changes to their investments in the company. US Bancorp DE increased its holdings of Catalent during the third quarter by 1.4%. US Bancorp DE owns 19,237 of the company’s shares valued at $1.392,000, after adding 272 more shares. Itau Unibanco Holding S.A. increased its position in Catalent in the third quarter by 372.7%. Itau Unibanco Holding S.A. owns now 3,134 shares valued at $227,000, after buying an additional 2,471 in the last quarter. Empirical Finance LLC increased its position in Catalent shares by 25.0% over the third quarter. Empirical Finance LLC owns 3,644 of the company’s shares worth $264,000, after adding 728 more shares during the last quarter. Inspire Investing LLC increased its stake in Catalent during the fourth quarter by 12.1%. Inspire Investing LLC owns 25,647 of the company stock, worth $1154,000. This is after purchasing an additional 2,775 during the last quarter. Asset Management One Co. Ltd. increased its stake in Catalent during the third quarter by 1.3%. Asset Management One Co. Ltd. owns 74 710 shares worth $5 406,000, after purchasing 952 additional shares in the last quarter. Hedge funds and institutional investors own 99.38% the company's stock.
Catalent Trading down 4.9 %
During trading hours, the price of the stock fell $2.24 to $43.19. The trading volume was 2,304,762 compared to the average of 2,706,637. The company's current ratio is 1.91. Its quick ratio is 1.38. And its debt-to equity ratio is 0.86. The company's 50-day moving median is $66.95, and its 200-day moving medium is $58.08. The company's market cap is $7.78 billion. It has a P/E of 19.09, P/E/G of 2.11, and beta of 1.17. Catalent's 1 year low is $40.69, and its 1 year high is $115.33.
The company last released its earnings on February 7th. The company's earnings per share for the first quarter were $0.62, which was $0.02 less than the consensus estimate ($0.64). Revenue for the quarter was $1.15 billion, which is higher than analysts' expectations of $1.1 billion. Catalent's net margin was 8.62%, and its return on equity was 11.40%. Analysts on the sell-side expect Catalent to post 2.85 earnings for this year.
Wall Street analysts forecast growth
Many analysts have made comments about the stock. Royal Bank of Canada raised their target price for shares of Catalent in a report published on Wednesday, 8th February from $73.00 up to $85.00. William Blair downgraded Catalent's rating from 'outperform to market perform' in a Friday research note. Bank of America raised their price target for Catalent in a research report on Wednesday, 8th February from $60.00 up to $78.00. Morgan Stanley raised their price target on Catalent to $85.00 from $81.00 and gave the company a 'overweight rating' in a report published on Thursday, 9th February. In a Monday research report, Deutsche Bank Aktiengesellschaft lowered their Catalent target price from $88.00 down to $72.00. Five analysts have given the stock a hold recommendation, while five others have assigned a buy recommendation. MarketBeat.com data shows that Catalent has a current consensus rating of "Hold" and an average price target of $88.50.
Catalent Company Profile
Catalent, Inc. is a holding firm that provides delivery technologies, develops and manufactures solutions for drugs, biologicals, cell, gene and other therapies, as well as consumer health products. It is organized into four segments: Softgel and Oral Technologies; Biologics; Oral and Specialty Deliveries and Clinical Supply Services.
MarketBeat.com offers a FREE daily email newsletter